Alpha-1-antitrypsin modified process - Grifols

Drug Profile

Alpha-1-antitrypsin modified process - Grifols

Alternative Names: Alpha-1 MP - Grifols; Alpha-1 proteinase-inhibitor-modified process - Grifols; Alpha-1-antitrypsin IV - Grifols; Alpha-1-protease-inhibitor-modified process - Grifols; Alpha-antitrypsin modified process - Grifols; Alpha1-PI; Prolastin C; Prolastin-C; TAL 6004

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer Grifols
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II Chronic fatigue syndrome; Type 1 diabetes mellitus

Most Recent Events

  • 31 Mar 2017 Grifols completes a phase-I/II trial in Alpha 1-antitrypsin deficiency in Japan (IV) (JapicCTI-163160)
  • 01 Nov 2016 Grifols Therapeutics initiates enrolment in a phase I/II trial for Alpha 1-antitrypsin deficiency in Japan (JapicCTI-163194)
  • 29 Mar 2016 Grifols Therapeutics initiates the extension phase III SPARTA-OLE trial for Alpha 1-antitrypsin deficiency in Denmark (IV) (EudraCT2015-004110-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top